10.09.2019: Press Release - Launch of the FLEXcyte 96
Launch of the FLEXcyte 96 – pushing the boundaries of cardiac safety screening.
Nanion Technologies is proud to announce the launch of the FLEXcyte 96 technology for cardiac contraction force measurements. Improving patient safety and reducing animal tests while saving time and money by replacing unnecessary in vivo experiments is the aim of this novel assay technology.
The FLEXcyte 96 has been developed in cooperation with innoVitro GmbH. Read the full press release here